Seonjeen Grace Shim, PHARMD in 11003, NY - Pharmacist

Seonjeen Grace Shim, PHARMD is a Pharmacist based in 11003, New York. Seonjeen Grace Shim is licensed to practice in New York (license number 058434) and her current practice location is 1797 Dutch Broadway, 11003, New York. She can be reached at her office (for appointments etc.) via phone at (516) 561-1340.

NPI number for Seonjeen Grace Shim is 1407282064 and her current mailing address is 1797 Dutch Broadway, 11003, New York. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1407282064.

Contact Information

	Seonjeen Grace Shim, PHARMD
	1797 Dutch Broadway, 11003, NY 11365-2334
	(516) 561-1340
	Not Available

Healthcare Provider's Profile

Full Name	Seonjeen Grace Shim
Gender	Female
Speciality	Pharmacist
Location	1797 Dutch Broadway, 11003, New York
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1407282064
Provider Enumeration Date: 09/15/2013
Last Update Date: 02/11/2014

Medical Identifiers

Medical identifiers for Seonjeen Grace Shim such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1407282064	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	058434 (New York)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Seonjeen Grace Shim is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Seonjeen Grace Shim, PHARMD 1797 Dutch Broadway, 11003, NY 11365-2334 Ph: () -	Seonjeen Grace Shim, PHARMD 1797 Dutch Broadway, 11003, NY 11365-2334 Ph: (516) 561-1340

News Archive

Pelosi calls for passage of comprehensive, affordable health insurance reform

"The President today made available to all Americans the Administration's health insurance reform proposal, which contains positive elements from the House and Senate-passed bills. I look forward to reviewing it with House Members and then joining the President and the Republican leadership at the Blair House meeting on Thursday. This discussion will continue a year-long historic level of transparency and open debate of this crucial reform effort.

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

High mobility group A genes are highly expressed in all aggressive cancers studied to date. These genes encode the high mobility group A (HMGA) proteins. In other words, these genes provide the genetic "code" necessary to produce HMGA proteins.

Biotime ships six ACTCellerate progenitor cell lines to Millipore

BioTime, Inc. announced today that it has initiated shipments of stem cell research products to its worldwide distributor, Millipore Corporation, according to the terms of the co-marketing agreement between the two companies that was announced on July 9, 2009. BioTime has shipped inventory of six ACTCellerate™ progenitor cell lines to Millipore and plans to begin shipments of additional cell lines and ESpan™ cell growth media in the next several weeks.

Baylor Health Care System opens new Diabetes Health and Wellness Institute in South Dallas

Baylor Health Care System announced today the opening of a new Diabetes Health and Wellness Institute in an underserved community in South Dallas that it believes will ultimately influence the way diabetes is treated and prevented around the country.

Advanced Life Sciences Holdings' Restanza promising against tularemia

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced positive top-line results from a pivotal, non-human primate study of its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) against an inhaled lethal dose of tularemia. A 14-day course of Restanza achieved a 100% survival rate at the doses tested. All of the ten animals in the study that received 16 mg/kg once-a-day of Restanza (approximate to a human dose of 300 mg) within 24 hours after exposure to a lethal dose of inhaled tularemia survived while only one of the ten animals that received placebo survived.

Seonjeen Grace Shim, PHARMD - Pharmacist in 11003, NY